Back to Journals » OncoTargets and Therapy » Volume 10

Upregulation of long noncoding RNA LOC440040 promotes tumor progression and predicts poor prognosis in patients with prostate cancer

Authors Zhang C, Liu C, Wu J, Zheng Y, Xu H, Cheng G, Hua L

Received 30 March 2017

Accepted for publication 6 August 2017

Published 11 October 2017 Volume 2017:10 Pages 4945—4954


Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 3

Editor who approved publication: Prof. Dr. Geoffrey Pietersz

Cheng Zhang,1,2,* Chunlin Liu,3,* Jie Wu,2,4,* Yuxiao Zheng,2 Haoxiang Xu,2 Gong Cheng,2 Lixin Hua2

Department of Urology, Gaoyou Traditional Chinese Medicine Hospital, Yangzhou 225600, 2Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, 3Department of Urology, The Second People’s Hospital of Taizhou, Taizhou, Jiangsu, 225500, 4Department of Urology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing 211100, People’s Republic of China

*These authors contributed equally to this work

Long noncoding RNAs (lncRNAs) play a functional role in the initiation and progression of prostate cancer (PCa). This study aimed to determine differentially expressed lncRNA through high-throughput sequencing technology and investigate its expression, biological function and clinical correlation with PCa.
Materials and methods: Candidate lncRNAs were identified through microarray screening and bioanalysis. The expression of lncRNA LOC440040 in PCa tissues and cell lines was determined by reverse-transcription polymerase chain reaction. The relationship between LOC440040 level and clinicopathological characteristics was analyzed by paired t-test or chi-square test, and its association with patient prognosis was assessed by the Kaplan–Meier method. The effects of LOC440040 on PC-3 and 22RV1 cells were evaluated by Cell Counting Kit-8 (CCK-8), migration, invasion and colony formation assays.
Results: LOC440040 expression was upregulated in PCa tissues and cell lines. Clinicopathological analysis showed that patients with high LOC440040 expression exhibited more advanced clinical features and shorter overall survival than those with low LOC440040 expression. Multivariate regression analysis revealed that LOC440040 expression was an independent prognostic factor in patients with PCa. Knockdown of LOC440040 inhibited PCa cell proliferation, migration and invasion.
Conclusion: LOC440040 may play an oncogenic role in PCa initiation and progression. This lncRNA could be a novel molecular prognostic biomarker and a potential therapeutic target for PCa.

Keywords: long noncoding RNA, LOC440040, prostate cancer, prognosis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]